Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib

Metastatic Renal Cell Carcinoma (mRCC) Clinical Trial

Official title:
An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib

Status Completed

Clinical Trial Summary

Patients with metastatic renal cell carcinoma (mRCC) who failed first-line therapy with sunitinib or pazopanib was treated with everolimus. Efficacy and safety of everolimus was evaluated in these patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma
Carcinoma, Renal Cell
Metastatic Renal Cell Carcinoma (mRCC)

Clinical Trial Details

NCT number	NCT01514448
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 4
Start date	May 21, 2012
Completion date	April 1, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04175262` - Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
Completed	`NCT02184416` - Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting
Recruiting	`NCT05287464` - International Multicentric Study ARON-1
Completed	`NCT01390519` - A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor	N/A